Intranasal Vaccination With Lipoproteins Confers Protection Against Pneumococcal Colonisation by Voss, Franziska et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/197175
 
 
 
Please be advised that this information was generated on 2019-06-02 and may be subject to
change.
ORIGINAL RESEARCH
published: 18 October 2018
doi: 10.3389/fimmu.2018.02405
Frontiers in Immunology | www.frontiersin.org 1 October 2018 | Volume 9 | Article 2405
Edited by:
Christophe Chevalier,
Institut National de la Recherche
Agronomique (INRA), France
Reviewed by:
Brian J. Akerley,
University of Mississippi Medical
Center, United States
Benfang Lei,
Montana State University,
United States
Abiodun David Ogunniyi,
University of South Australia, Australia
*Correspondence:
Sven Hammerschmidt
sven.hammerschmidt@
uni-greifswald.de
Specialty section:
This article was submitted to
Vaccines and Molecular Therapeutics,
a section of the journal
Frontiers in Immunology
Received: 18 July 2018
Accepted: 28 September 2018
Published: 18 October 2018
Citation:
Voß F, Kohler TP, Meyer T,
Abdullah MR, van Opzeeland FJ,
Saleh M, Michalik S, van Selm S,
Schmidt F, de Jonge MI and
Hammerschmidt S (2018) Intranasal
Vaccination With Lipoproteins Confers
Protection Against Pneumococcal
Colonisation. Front. Immunol. 9:2405.
doi: 10.3389/fimmu.2018.02405
Intranasal Vaccination With
Lipoproteins Confers Protection
Against Pneumococcal Colonisation
Franziska Voß 1, Thomas P. Kohler 1, Tanja Meyer 2, Mohammed R. Abdullah 1,
Fred J. van Opzeeland 3, Malek Saleh 1, Stephan Michalik 2, Saskia van Selm 3,
Frank Schmidt 2,4, Marien I. de Jonge 3 and Sven Hammerschmidt 1*
1Department of Molecular Genetics and Infection Biology, Center for Functional Genomics of Microbes, Interfaculty Institute
of Genetics and Functional Genomics, University of Greifswald, Greifswald, Germany, 2Department of Functional Genomics,
Center for Functional Genomics of Microbes, Interfaculty Institute of Genetics and Functional Genomics, University Medicine
Greifswald, Greifswald, Germany, 3 Section Pediatric Infectious Diseases, Laboratory of Medical Immunology, Radboud
Center for Infectious Diseases, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen,
Netherlands, 4 ZIK-FunGene, Department of Functional Genomics, Interfaculty Institute for Genetics and Functional
Genomics, University Medicine Greifswald, Greifswald, Germany
Streptococcus pneumoniae is endowed with a variety of surface-exposed proteins
representing putative vaccine candidates. Lipoproteins are covalently anchored to
the cell membrane and highly conserved among pneumococcal serotypes. Here, we
evaluated these lipoproteins for their immunogenicity and protective potential against
pneumococcal colonisation. A multiplex-based immunoproteomics approach revealed
the immunogenicity of selected lipoproteins. High antibody titres were measured in sera
from mice immunised with the lipoproteins MetQ, PnrA, PsaA, and DacB. An analysis of
convalescent patient sera confirmed the immunogenicity of these lipoproteins. Examining
the surface localisation and accessibility of the lipoproteins using flow cytometry indicated
that PnrA and DacB were highly abundant on the surface of the bacteria. Mice were
immunised intranasally with PnrA, DacB, and MetQ using cholera toxin subunit B (CTB)
as an adjuvant, followed by an intranasal challenge with S. pneumoniae D39. PnrA
protected the mice from pneumococcal colonisation. For the immunisation with DacB
and MetQ, a trend in reducing the bacterial load could be observed, although this effect
was not statistically significant. The reduction in bacterial colonisation was correlated
with the increased production of antigen-specific IL-17A in the nasal cavity. Immunisation
induced high systemic IgG levels with a predominance for the IgG1 isotype, except for
DacB, where IgG levels were substantially lower compared toMetQ and PnrA. Our results
indicate that lipoproteins are interesting targets for future vaccine strategies as they are
highly conserved, abundant, and immunogenic.
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INTRODUCTION
Streptococcus pneumoniae continues to be amajor cause of life-threatening invasive diseases such as
pneumonia, sepsis and meningitis, especially in young children, the elderly and immunodeficient
people (1). Two different types of vaccines are currently recommended by the World Health
Organization (WHO) for the prevention of pneumococcal infections: the 23-valent polysaccharide
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vaccine (PPV23) and the pneumococcal conjugate vaccines
PCV7, PCV10, and PCV13 (2). Despite their proven efficacy
(3, 4), these vaccines have some important limitations, including
restricted serotype coverage, which may facilitate replacement by
non-vaccine serotypes, and high manufacturing costs (5–7). It is
therefore vital to develop a new generation of vaccines, which can
provide serotype-independent protection against pneumococcal
infections, while being affordable for developing countries.
The pneumococcal cell-surface is decorated with a variety of
proteins, which are exposed to the extracellular milieu of the
host and are therefore the most promising targets for future
protein-based vaccines. Consequently, pneumococcal surface
proteins have been extensively studied over the last two decades,
with the majority being characterised as virulence factors.
Promising vaccine candidates, including PspA (Pneumococcal
surface protein), PhtD (Pneumococcal histidine triad), PcpA
(Pneumococcal choline-binding protein), PcsB (Pneumococcal
cell wall separation protein), and StkP (serine/threonine protein
kinase), have already been shown to be safe and immunogenic in
clinical trials (8).
In this study, we particularly focussed on the lipoproteins,
which are embedded in the pneumococcal cell membrane via
a covalently anchored lipid moiety. Lipoproteins are highly
conserved, and many of them influence pneumococcal fitness
and virulence (9–14). Some studies have indicated the protective
potential of lipoproteins against pneumococcal infections,
with the well-characterised lipoprotein pneumococcal surface
antigen A (PsaA), a manganese substrate-binding protein, being
particularly in the research spotlight. PsaA is expressed by all
serotypes of S. pneumoniae and is known to bind to human
E-cadherin, thereby acting as an adhesin (15–19). Moreover,
PsaA is highly immunogenic, as shown by the increased
antibody responses that have been described as a result of
pneumococcal exposure in children (20–22). Using intranasal
challengemodels inmice, PsaA has been shown to protect against
pneumococcal carriage, demonstrated by reduced bacterial loads
in the nasopharynx (23). A multivalent recombinant subunit
protein vaccine containing PsaA, StkP, and PcsB was tested in
a phase I trial (IC47, Intercell AG, Austria, NCT00873431) and
shown to be safe and immunogenic (24, 25), resulting in the
induction of protective antibodies against all three proteins.
Besides PsaA, two other lipoproteins, SP_0148 and SP_2108, have
emerged as promising vaccine candidates. Following intranasal
immunisation, these proteins, which function as substrate-
binding proteins for ABC transporters, showed protective
efficacy in a mouse model of colonisation, which correlated with
the observed elevation in IL-17A levels and depended on Toll-
like receptor 2 signalling (26). Recently, Genocea Biosciences
tested the GEN-004 vaccine (SP_0148, SP_2108 and SP_1912)
using a human challenge model. Although the differences
were not statistically significant, there was a trend in reducing
carriage acquisition by 18–36% vs. the placebo (27), supporting
the further development of GEN-004 and indicating the high
potential of lipoproteins as components of a protein-based
vaccine.
We therefore focused in our study on pneumococcal
lipoproteins, aiming to identify new and promising candidates
for a protein-based and serotype-independent vaccine. We
analysed the immunogenicity of our candidates in mouse
immunisation studies and by screening convalescent patient
sera, while also assessing their abundance on the surface of
pneumococci. It is essential that the antibodies raised by
immunisation can recognise and bind to accessible surface
proteins. Three lipoproteins were identified as the most
promising candidates based on their high levels of conservation,
their immunogenicity and their abundance on the pneumococcal
cell-surface: the L,D-carboxypeptidase DacB (9), the methionine-
binding protein MetQ (12), and the nucleoside-binding protein
PnrA (11). DacB is a cell wall hydrolase and therefore essential for
pneumococcal peptidoglycan turnover and the preservation of
cell shape (9). MetQ and PnrA are substrate-binding lipoprotein
components of the ABC transporters responsible for methionine
or nucleoside uptake, respectively, from the extracellular space
(11, 12). Pneumococcal mutants lacking these lipoproteins were
previously shown to have significantly attenuated virulence in
either systemic or pulmonary mouse infection models, although
there is contradictory information regarding the role of MetQ in
causing systemic infection in mice (9, 11, 12, 28, 29).
In our study, intranasal vaccination with these lipoproteins
resulted in a reduced bacterial load in the nasal cavity, which
correlated with increased nasal IL-17A levels. Humoral immune
responses were characterised by high serum levels of IgG1
and substantial IgG2 levels, with the exception of the DacB
vaccination. Our findings demonstrate the high potential of
DacB and PnrA in particular for use in a future protein-based
pneumococcal vaccine.
MATERIALS AND METHODS
Ethics Statement
All animal experiments were conducted in accordance with
the guidelines of the ethics committee at the University
of Greifswald, the German regulations of the Society for
Laboratory Animal Science (GV-SOLAS) and the European
Health Law of the Federation of Laboratory Animal Science
Associations (FELASA). All experiments were approved by
the Landesamt für Landwirtschaft, Lebensmittelsicherheit und
Fischerei Mecklenburg-Vorpommern (LALLF M-V, Rostock,
Germany) and the LALLF M-V ethical board (LALLF M-V
permit no. 7221.3-1-061/17). All efforts were made to minimise
the discomfort of the animals and ensure the highest ethical
standards.
Bacterial Strains, Culture Conditions, and
Pneumococcal Mutant Construction
Streptococcus pneumoniae wild-type and isogenic deletion
mutants (Table 1) were grown on Columbia blood agar
plates (Oxoid) supplemented with the appropriate antibiotics
(50µg/ml kanamycin, 5µg/ml erythromycin or 10µg/ml
trimethoprim) and cultivated to mid-log phase (A600 = 0.35–
0.40) in THY containing 36.4% Todd-Hewitt broth (Roth)
and 0.5% yeast extract (Roth) at 37◦C and in 5% CO2.
Escherichia coli strains were cultured on solid Luria-Bertani
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(LB) medium plates or in liquid LB medium (Roth) to mid-
log phase (A600 = 0.8) on an environmental shaker in the
presence of kanamycin (50µg/ml), ampicillin (100µg/ml),
and/or erythromycin (250µg/ml) at 30◦C. To generate the
1metQ (sp_0149), 1sp_0191, 1pnrA (sp_0845), 1sp_0899, and
1adcAII (sp_1002) mutants, the loci of the respective genes
and their upstream and downstream flanking sequences were
amplified from S. pneumoniae TIGR4 genomic DNA using
PCR and the primer pairs listed in Table 2. Following the
manufacturer’s instructions, the PCR products were directly
cloned into pGEM R©-T Easy vectors (Promega, Madison, WI,
USA) and transformed into E. coli DH5α competent cells.
The recombinant plasmids p559, p560, p576, p573, and p572
harbouring the desired DNA inserts were purified and used as
templates for inverse PCR reactions with the primer pairs listed
in Table 2. The deleted sequences were replaced with the ermB
resistance gene, which was amplified from plasmid pE89 using
PCR with the primer pair ermB_105/ermB_106 (Table 2). These
recombinant plasmids were used to transform pneumococci, as
described previously (35). The non-encapsulated pneumococcal
mutants D391psaA, D391pspA, D391ppmA, and D391slrA
were generated by transformation with the recombinant plasmid
p873, in which the capsule gene locus is replaced by the aphA3
resistance gene.
Heterologous Expression, Purification of
Recombinant Proteins, and Production of
Polyclonal Antisera
The N-terminally His6-tagged proteins used in this study were
either described previously (Table 2) or were generated by
cloning the PCR products of the target genes metQ, sp_0191,
pnrA, sp_0899, and adcAII, without their signal sequences,
into the pTP1 expression vector (10). PCR reactions were
performed using S. pneumoniae TIGR4 chromosomal DNA
as a template and the primer pairs listed in Table 2. The
primers contained restriction sites (NheI/SacI, NheI/HindIII, or
NdeI/HindIII), which were used to ligate the fragments into
similarly digested expression vectors. The resulting plasmids
(Table 1) were transformed into competent E. coli BL21 (DE3).
For protein production, the recombinant E. coli BL21 (DE3)
were cultured in LB, supplemented with kanamycin (50µg/ml)
or ampicillin (100µg/ml), to an A600 of 0.6–0.8 at 30◦C. Protein
expression was induced with 1mM IPTG (isopropyl-β-D-1-
thiogalactopyranoside; Hartenstein, Wuerzburg, Germany) and
the cells were cultured for another 3 h. The resulting His6-tagged
proteins were purified using affinity chromatography in a His
TrapTM HP Ni-NTA column (1ml; GE Healthcare, Chicago, IL,
USA) on the ÄKTA Purifier liquid chromatography system (GE
Healthcare), following the manufacturer’s instructions. Purified
proteins were dialysed (12–14 kDa molecular weight cut off)
against phosphate-buffered saline (PBS; pH 7.4). The absorbance
of the proteins was determined at A280 using a NanoDrop
R© ND-
1000 (Thermo Fisher Scientific, Waltham, MA, USA) to calculate
the protein concentrations while considering the extinction
coefficients and molecular weights. After sodium dodecyl
sulphate polyacrylamide gel electrophoresis (SDS-PAGE), the
purity of the proteins was analysed using silver staining and
immunoblotting (Figure 1) with an anti-Penta-His-tag mouse
antibody (Qiagen, Hilden, Germany). The recombinant proteins
were used in intraperitoneal immunisations using ImjectTM Alum
as an adjuvant (Thermo Fisher Scientific). Six- to eight-week-
old female CD-1 mice (Charles River Laboratories, Sulzfeld,
Germany) were vaccinated by intraperitoneal injection with
100 µl of a 1:1 emulsion containing 20 µg recombinant protein
and the adjuvant. The mice received vaccine boosters at days 14
and 28 and were bled after 6 weeks. Serum samples were taken
before each immunisation step (pre-immune, priming, 1st boost)
and 2 weeks after the third immunisation (post-immune) and
stored at−20◦C until use.
Purification of Polyclonal IgG and
Immunoblotting
Polyclonal IgGs were purified from the generated antisera using
protein A-sepharose chromatography. Protein A sepharose CL-
4B columns (GE Healthcare), stored in 20% ethanol at 4◦C,
were equilibrated in binding buffer (50mM Tris-HCl, pH 7.0).
After mixing the antisera with one volume of binding buffer,
the mixture was applied to the column and incubated for
15min at room temperature (RT). The column was washed
with binding buffer until the absorption measured using a
NanoDrop R© ND-1000 dropped below A280 = 0.05. The elution
was performed using 1-ml aliquots of elution buffer (100mM
glycine, pH 3.0) collected in 50 µl phosphate buffer (50mM
K2HPO4, pH 8.5). The IgG concentration of each sample
was determined by measuring the absorption at A280 using
a NanoDrop R© ND-1000. Immunoblots were carried out to
analyse the specificity of the purified polyclonal IgGs. After the
SDS-PAGE-mediated separation of bacterial lysates from late
exponential growth phase cells, the proteins were transferred
onto a nitrocellulose membrane using semidry blotting (Bio-
Rad Laboratories, Hercules, CA, USA). The membrane was
blocked with 5% skim milk (in Tris-buffered saline (TBS), Roth)
overnight at 4◦C. Following an incubation withmouse polyclonal
IgGs (1:1,000 in blocking buffer) recognising lipoproteins or
rabbit anti-enolase serum (1:25,000 in blocking buffer) for 1 h
at RT, the membrane was washed three times with washing
buffer (TBS, 0.05% Tween R© 20). A secondary antibody, goat
anti-mouse IgG (Dianova, Hamburg, Germany; 1:5,000) or
goat anti-rabbit IgG (Dianova; 1:5,000) horseradish peroxidase
conjugate was used for 1 h at RT, then washed three times with
washing buffer. Finally, antibody binding was detected using an
enhanced chemiluminescence reaction (luminol and p-coumaric
acid, Roth).
Antibody Titration of Polyclonal IgGs Using
Enzyme-Linked Immunosorbent Assays
(ELISAs) and the Flow Cytometric Analysis
of Surface Abundance
The antibody titres of polyclonal IgGs were determined using
ELISAs. Microtiter plates (96-well, PolySorp R©, Nunc, Thermo
Fisher Scientific) were coated with equimolar amounts of
pneumococcal proteins (30 pmol/well) overnight at 4◦C. The
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TABLE 1 | Strain and plasmid list.
Strain/plasmid Serotype and relevant genotype Resistance* Source or reference
Streptococcus pneumoniae
SP257 (D39) 2 None NCTC7466
PN111 D391cps Kmr (30, 31)
PN282 D391cps1adcAII (spd_0888) Kmr, Ermr This work
PN279 D391cps1dacB (spd_0549) Kmr, Ermr (9)
PN253 D391cps1etrx1 (spd_0572) Kmr, Ermr (10)
PN281 D391cps1etrx2 (spd_0886) Kmr, Ermr (10)
PN238 D391cps1metQ (spd_0151) Kmr, Ermr This work
PN732 D391cps1ppmA (spd_0868) Kmr, Trmr This work
PN280 D391cps1pnrA (spd_0739) Kmr, Ermr This work
PN301 D391cps1psaA (spd_1463) Kmr, Ermr This work
PN733 D391cps1slrA (spd_0672) Kmr, Ermr This work
PN241 D391cps1spd_0179 Kmr, Ermr This work
PN312 D391cps1spd_0792 Kmr, Ermr This work
PN735 D391cps1pspA (spd_0126) Kmr, Ermr This work
PN278 D391adcAII (spd_0888) Ermr This work
PN275 D391dacB (spd_0549) Ermr (9)
PN246 D391etrx1 (spd_0572) Ermr (10)
PN277 D391etrx2 (spd_0886) Ermr (10)
PN311 D391metQ (spd_0151) Ermr This work
PN093 D391ppmA (spd_0868) Trmr (32)
PN276 D391pnrA (spd_0739) Ermr This work
PN172 D391psaA (spd_1463) Ermr (13)
PN095 D391slrA (spd_0672) Ermr (32)
PN243 D391spd_0179 Ermr This work
PN251 D391spd_0792 Ermr This work
PN031 D391pspA (spd_0126) Ermr (33)
Escherichia coli
DH5α 1(lac)U169, endA1, gyrA46, hsdR17, Φ801(lacZ)M15, recA1,
relA1, supE44, thi-1
None Bethesda Research Labs, Gaithersburg,
U.S.
BL21(DE3) E. coli B, F- dcm ompT hsdS gal λ(DE3), T7 polymerase gene
under control of the lacUV5 promoter
None Novagen, Merck KGaA, Darmstadt,
Germany
Plasmids
pGEM®-T easy TA cloning vector for PCR products Apr Madison, U.S.
p89 pCR2.1Topo with erythromycin (ermB) cassette Apr, Kmr, Ermr (34)
p873 pGXT with capsule locus replaced by aphA3 gene resistance
cassette, flanking genes dex ,and aliA
Apr, Kmr (10)
p572 pGEM-T derivative with sp_1002 (adcAII)
5′ and 3′ flanking region for mutagenesis
Apr This work
p598 pGEM-T derivative with sp_1002 (adcAII)
interrupted by ermB gene resistance cassette
Apr, Ermr This work
p559 pGEM-T derivative with sp_0149 (metQ)
5′ and 3′ flanking region for mutagenesis
Apr (28)
p563 pGEM-T derivative with sp_0149 (metQ)
interrupted by ermB gene resistance cassette
Apr, Ermr (28)
p576 pGEM-T derivative with sp_0845 (pnrA)
5′ and 3′ flanking region for mutagenesis
Apr This work
p646 pGEM-T derivative with sp_0845 (pnrA)
interrupted by ermB gene resistance cassette
Apr, Ermr This work
p560 pGEM-T derivative with sp_0191 (spd_0179)
5′ and 3′ flanking region for mutagenesis
Apr This work
p565 pGEM-T derivative with sp_0191 (spd_0179)
interrupted by ermB gene resistance cassette
Apr, Ermr This work
p573 pGEM-T derivative with sp_0899 (spd_0792)
5′ and 3′ flanking region for mutagenesis
Apr This work
(Continued)
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TABLE 1 | Continued
Strain/plasmid Serotype and relevant genotype Resistance* Source or reference
p577 pGEM-T derivative with sp_0899 (spd_0792)
interrupted by ermB gene resistance cassette
Apr, Ermr This work
pTP1 pET28 expression vector, N-terminal His-tag, TEV protease
cleavage site, induction by IPTG
Kmr, Ermr (10)
p648 pTP1 with TIGR4 sp_1002 (adcAII) for protein production and
mice immunisation
Kmr This work
p652 pTP1 with TIGR4 sp_0629 (dacB) for protein production and mice
immunisation
Kmr (9)
p629 pTP1 with TIGR4 sp_0659 (etrx1) for protein production and mice
immunisation
Kmr (10)
p651 pTP1 with TIGR4 sp_1000 (etrx2) for protein production and mice
immunisation
Kmr (10)
P732 pTP1 with TIGR4 sp_0149 (metQ) for protein production and mice
immunisation
Kmr This work
p264 pET11a with R6 spr0884 (ppmA) for protein production and mice
immunisation
Kmr (32)
p649 pTP1 with TIGR4 sp_0845 (pnrA) for protein production and mice
immunisation
Kmr This work
p653 pTP1 with TIGR4 sp_1650 (psaA) for protein production and mice
immunisation
Kmr This work
p263 pET11a with R6 spr0679 (slrA) for protein production and mice
immunisation
Kmr (32)
p628 pTP1 with TIGR4 sp_0191 (spd_0179) for protein production and
mice immunisation
Kmr This work
p631 pTP1 with TIGR4 sp_0899 (spd_0792) for protein production and
mice immunisation
Kmr This work
p105 pQE30 with PspA (aa 32-289) without choline-binding domain Apr (33, 68)
*Kmr , Kanamycin; Ermr , Erythromycin; Apr , Ampicillin; Trmr , Trimethoprim.
plates were washed three times with washing buffer (PBS, pH
7.4, 0.05% Tween R© 20) and blocked with blocking buffer (PBS,
0.1% Tween R© 20 supplemented with 2% bovine serum albumin)
for 1 h at RT. The wells were washed and incubated for 1 h
at RT with polyclonal IgGs in serial dilutions ranging from
1:750 to 1:24,000 in blocking buffer. Antibody binding was
detected using goat anti-mouse IgG coupled to horseradish
peroxidase (1:1,000, Jackson ImmunoResearch Laboratories,
Inc., Ely, UK) as the secondary antibody (1 h incubation at
RT). For the detection, 0.03% H2O2 and o-phenylenediamine
dihydrochloride (OPD, Agilent Technologies, Santa Clara, CA,
USA) at a final concentration of 0.67 mg/ml were used in a
colorimetric reaction, which was stopped by adding 2M H2SO4.
The absorbance of each sample was measured at A492 using the
FLUOstar Omega Microplate Reader (BMG Labtech, Ortenberg,
Germany). This resulted in hyperbolic titration curves (y =
Bmax·x
Kd+x
, Bmax, maximal binding; Kd, concentration for half the
maximal binding), which were used to calculate the relative IgG
concentrations. The absorbance was therefore set to A492 = 0.3
(y) in the linear dynamic range and the IgG concentrations (x)
were calculated and denoted as the 1× end concentration in the
flow cytometry. The polyclonal IgGs with equal contents of IgGs
specific to the lipoproteins were therefore applied to enable the
comparison of surface abundances.
For flow cytometry, S. pneumoniae wild-type D39, its capsule-
deficient derivative (D391cps) and the isogenic mutants were
cultured in 30ml THY to A600 0.35–0.4. The bacteria were
washed with PBS, then resuspended in 1ml of PBS. To detect
the proteins on the surface of the pneumococci, 2 × 108
bacteria were incubated with mouse polyclonal IgG (1×, 5×,
10×, 20×, and 50× end concentration in PBS) for 45min
at 4◦C. The bacteria were washed with PBS and stained
using secondary antibody goat anti-mouse IgG Alexa-Fluor-
488 conjugate (1:1,000; Thermo Fisher Scientific). After another
45-min incubation at 4◦C, the bacteria were washed with
PBS and fixed with 1% paraformaldehyde overnight at 4◦C.
The flow cytometry was conducted using a FACSCaliburTM
(BD Biosciences, Heidelberg, Germany), and the CellQuestPro
Software 6.0 (BD Biosciences) was used for data acquisition.
The data were analysed using Flowing Software 2.5.1 (by Perttu
Terho, Turku Centre for Biotechnology). The bacteria were
detected and gated as described previously (36).
Intranasal Immunisation and
Pneumococcal Challenge of Mice
Seven-week-old female C57BL/6 mice (n = 12; Charles River
Laboratories) were intranasally immunised three times at 2-
week intervals under anaesthesia (50mg ketamine and 5mg
xylazine per kg mouse weight). The 10 µl vaccine contained
5 µg recombinant DacB, MetQ, PnrA, or PspA proteins in
combination with 4 µg cholera toxin subunit B (CTB; Sigma-
Aldrich, St. Louis, MO, USA) in PBS. Control mice were mock-
treated with an equivalent volume of PBS and adjuvant. Three
weeks after the last vaccination, the mice were infected with
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TABLE 2 | Primer list.
Primer use Primer Sequence (5′-3′)*
INSERTION-DELETION MUTAGENESIS
Amplification of sp_1002 + 5′ and 3′ flanking
region
adcAII_427
adcAII_430
5′-CTACTA GAATTCGATGATGCCGTTGCCTTT-3′
5′-TTCCAAGCTGCAGATCCCTGCTTCCCATTCC-3′
Inverse PCR of sp_1002 + 5′ and 3′ flanking
region (pGEM-T Easy)
adcAII_429
adcAII_428
5′-CTCACTGAAGCTTGACCCACAAAATGACAAGACC-3′
5′-ATCATCGAAGCTTCCCCCAAGCACAAAAGAA-3′
Amplification of sp_0149 + 5′ and 3′ flanking
region
metQ_382
metQ_385
5′-CTACTACTAGAATTCATGCTGAACACACGGACAAC-3′
5′-AACCTTCCAAGCTGCAGCCGCTCCCTCCATGATAAAG-3′
Inverse PCR of sp_0149 + 5′ and 3′ flanking
region (pGEM-T Easy)
metQ_384
metQ_383
5′-ACTCACTCACTGAAGCTTATCGCAGCTTACCACACAGA-3′
5′-ATCATCATCATCGAAGCTTAGCCAAACCTGCGACTGTAG-3′
Amplification of sp_0845 + 5′ and 3′ flanking
region
pnrA_415
pnrA_418
5′-CTACTAGAATTCAAAAAGCTGGGGCTGAC-3′
5′-CCAAGCTGCAGCGGTCAGAAACTGCTCGAAT-3′
Inverse PCR of sp_0845 + 5′ and 3′ flanking
region (pGEM-T Easy)
pnrA_417
pnrA_416
5′-CTCACTGCTCGAGTGGAAGCGTAAAAGTTCCTGA-3′
5′-ATCATCGGTACCGAGCGGTTACCACATGCAG-3′
Amplification of sp_0191 + 5′ and 3′ flanking
region
sp_0191_392
sp_0191_395
5′-CTACTACTAGAATTCATGTAGCGAAAGGGGTAGG-3′
5′-AACCTTCCAAGCTGCAGCTTTGCTCCGTAGGCTTGAC-3′
Inverse PCR of sp_0191 + 5′ and 3′ flanking
region (pGEM-T Easy)
sp_0191_394
sp_0191_393
5′-ACTCACTCACTGAAGCTTATGGCGCGACAGAACAATAG-3′
5′-ATCATCATCATCGAAGCTTAACCAACCAGGACAAAAAGG-3′
Amplification of sp_0899 + 5′ and 3′ flanking
region
sp_0899_419
sp_0899_422
5′-CTACTAGAATTCCCTTGTCTGGGTGGTTCC-3′
5′-CCAAGCTGCAGTGGGACTAGCGCCAGAA-3′
Inverse PCR of sp_0899 + 5′ and 3′ flanking
region (pGEM-T Easy)
sp_0899_421
sp_0899_420
5′-CTCACTGCTCGAGGCGAGGGACTGGCTAA-3′
5′-ATCATCGGTACCCAAGCAGCCAAGCCTAAAA-3′
ANTIBIOTIC CASSETTE AMPLIFICATION
Erythromycin (ermB) ermB_105 5′-GATGATGATGATCCCGGGTACCAAGCTTGAATTCA
CGGTTCGTGTTCGTGCTG-3′
ermB_106 5′-AGTGAGTGAGTCCCGGGCTCGAGAAGCTTGAATTCGTAGG
CGCTAGGGACCTC-3′
RECOMBINANT PROTEIN PRODUCTION
sp_0899 (TIGR4) sp_0899_463
sp_0899_464
5′-GCGCGCTAGCCAACAACAACATGCTACTTC-3′
5′-GGCCGAGCTCTTAAAGTTTAACCCACTTATC-3′
sp_1002 (TIGR4; adcAII) adcAII_451
adcAII_452
5′-GGGCGCTAGCGGTCAAAAGGAAAGTCAGAC-3′
5′-GCGGCCAAGCTTACTTTAATTCTTCTGCTAG-3′
sp_0149 (TIGR4; metQ) metQ_410
metQ_391
5′-AAAGCATATGAGCGGCGAAAACCTGTATTTTCAG
GGCGCTAGCGGAAACTCAGAAAAGAAAGC-3′
5′-CCAACCTTCCAAGCTTACCAAACTGGTTGATCC-3′
sp_0845 (TIGR4; pnrA) pnrA_449
pnrA_450
5′-AAGCGCTAGCGGTAACCGCTCTTCTCGTA-3′
5′-GGGGCCAAGCTTATTTTTCAGGAACTTTTACGC-3′
sp_1650 (TIGR4; psaA) psaA_488
psaA_489
5′-GCGCGCTAGCGGAAAAAAAGATAC-3′
5′-GCGCAAGCTTATTTTGCCAATCCTTCAG-3′
sp_0191 (TIGR4) sp_0191_392
sp_0191_393
5′-TATTTTCAGGGCGCTAGCGGACAGAAAAAAGAAACTGG-3′
5′-CCAACCTTCCAAGCTTATTGTTCTGTCGCGCCATTTG-3′
*Restriction sites used for cloning are underlined.
10 µl PBS containing 3.4 × 106 CFU of S. pneumoniae D39.
Three days after the bacterial challenge, the mice were euthanised
and their blood and nasal tissues were harvested. Nasal tissue
was homogenised in 1ml PBS using a T10 basic blender (IKA,
Staufen, Germany), and serially diluted samples were plated
on blood agar (Oxoid) to quantify the recovered bacteria (log
CFU/ml). Serum samples were taken before each immunisation
step (pre-immune, priming, 1st boost), 2 weeks after the third
immunisation (post-immune) and after the challenge with
pneumococci. They were stored at−20◦C until use.
Detection of Local IL-17A in the
Nasopharyngeal-Associated Lymphoid
Tissue (NALT)
Cytokine production in mouse nasal samples was determined
using a bead-based immunoassay (Bio-Rad Laboratories),
according to manufacturer’s instructions. The assay was
performed using the Bio-Plex ProTM Reagent Kit, the Bio-Plex
ProTM mouse cytokine IL-17A set and the Bio-Plex ProTM mouse
cytokine standard group I, 23-Plex. The concentrations were
calculated using Graph Pad Prism 5.
Local and Systemic Antibody and Isotype
Levels
Local IgG and IgA levels in the nasal tissue and the systemic total
levels of IgG, IgG1, and IgG2a/IgG2c isotype were determined
in the post-immune (Alum immunisation) or post-challenge
sera (CTB immunisation) using an ELISA. PolySorp R© Microtiter
plates (96-well, Nunc, Thermo Fisher Scientific) were coated with
equimolar amounts of pneumococcal proteins (3 pmol/well) and
stored overnight at 4◦C. The plates were washed and blocked
as described above, then the wells were incubated with samples
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diluted in blocking buffer for 1 h at 37◦C. The IgA and IgG
levels in the nasal tissue samples were detected using 1:2 and 1:10
dilutions, respectively. Post-immune (immunisation only) and
post-challenge sera (immunisation and challenge) were serially
diluted ranging from 1:100 to 1:60,000 or 1:50 to 1:10,000,
respectively. The plates were washed and incubated for 1 h at RT
with horseradish peroxidase coupled with rabbit anti-mouse total
IgG (Jackson ImmunoResearch Laboratories, Inc.), rabbit anti-
mouse IgG1 (Sigma-Aldrich), goat anti-mouse IgG2a (Sigma-
Aldrich), goat anti-mouse IgG2c (Abcam, Cambridge, UK), or
goat anti-mouse IgA antibody (Sigma-Aldrich). The protection
study using CTB as an adjuvant was carried out in C57BL/6 mice,
which express IgG2c instead of IgG2a due to a gene replacement
(37). These mice were therefore isotyped for IgG2c rather than
the IgG2a used for the CD-1 mice. Detection was performed
as described above. The antibody titre of each serum specimen
was denoted as the log10 of its reciprocal dilution of the serum
giving twice the average absorbance of the sera derived from the
PBS-treated group.
Monitoring of Antibody Titres Directed
Against Pneumococcal Lipoproteins Using
a FLEXMAP 3D® Analysis
The bead-based flow cytometric technique FLEXMAP 3D R©
(Luminex Corporation) was applied to simultaneously quantify
the antibodies directed against the 12 pneumococcal surface
proteins. This analysis was carried out as described recently (38),
using the same commercially available reagents and instruments.
Purified His6-tagged proteins were covalently coupled to 6.25
× 105 fluorescent FLEXMAP 3D R© MagPlex R© beads. The beads
were protected from light throughout the workflow to avoid
photo bleaching, and all incubation steps were carried out under
agitation (900 rpm). After three washes with 100mMmonobasic
sodium phosphate (activation buffer, pH 6.2) using a magnetic
96-well separator, the carboxyl groups on the surface of the
beads were activated for 20min by a resuspension in activation
buffer (5 mg/ml each of EDC and sulpho-NHS). The activated
beads were washed three times with coupling buffer [50 mmol/l
2-(N-morpholino)ethanesulphonic acid, pH 5.0] followed by a
2-h incubation with 125 µl recombinant S. pneumoniae protein
solution (100µg/ml). The coupled beads were washed three times
with washing buffer (PBS, 0.05% (v/v) Tween R© 20, pH 7.4) and
adjusted to a concentration of 125 beads per µl using blocking-
storage buffer (1% (w/v) bovine serum albumin and 0.05% (v/v)
ProClinTM 300 in PBS, pH 7.4). The beads were stored at 4◦C
until use. A coupling control was applied to validate the coupling
efficiency. Amaster mix of sonicated coupled beads was prepared
by diluting the beads 1:50 in bead buffer [50% (v/v) blocking-
storage buffer and 50% (v/v) LowCross-Buffer R© (LCB)]. After
incubation with the anti-Penta-His tag mouse antibody (final
concentration 10µg/ml) for 45min, the beads were washed
three times with washing buffer and stained for 30min using
R-phycoerythrin (RPE)-conjugated goat anti-mouse IgG (final
concentration 5µg/ml). After another washing procedure, the
beads were resuspended in 100 µl xMAP R© Sheath Fluid and
measured in the Luminex R© FLEXMAP 3D R© system with the
following instrumental setup: sample size 80 µl, sample timeout
60 s, bead count 10,000, and gate settings 7,500–15,000 under
standard PMT (Photomultiplier tube) settings.
A multiplex immunoassay was used to compare differences in
the amounts of anti-pneumococcal antibodies in serum samples
obtained from 22 patients convalescent from pneumococcal
infections. Convalescent-phase sera were kindly provided by
Gregor Zysk, University of Düsseldorf, Germany (39). The
infections included pneumonia (n = 6), meningitis (n = 7),
sepsis (n = 4), and unknown clinical outcomes (n = 5), which
were all caused by different pneumococcal serotypes. In addition,
post-immune sera (2 weeks after the third immunisation) were
obtained from CD-1 mice (n = 6) intraperitoneally immunised
with ImjectTM Alum or C57BL/6 mice intranasally immunised
with CTB as an adjuvant, and were analysed to determine their
antibody titres for the indicated proteins.
For the multiplex assay, serum samples were serially diluted
(1:50, 1:500, 1:1,000, 1:10,000, 1:25,000, 1:50,000 and 1:100,000)
in assay buffer (90% (v/v) bead buffer and 10% (v/v) E. coli
BL21 lysate) and incubated for 20min at RT to block unspecific
binding. A bead master mix was prepared with a bead count of
1,000 per well. A 50-µl aliquot of the diluted sample was added to
the beads and incubated overnight at 4◦C, after which the beads
were washed three times with 100 µl washing buffer. The beads
were incubated with 50 µl RPE-conjugated goat anti-human IgG
(final concentration 5µg/ml) or 50 µl RPE-conjugated goat anti-
mouse IgG (final concentration 5µg/ml) for 1 h at RT. After three
washes with 100 µl washing buffer, the beads were resuspended
in 100 µl xMAP R© Sheath Fluid (InvitrogenTM) and measured
in the Luminex R© FLEXMAP 3D R© system using the following
instrumental setup: sample size 80 µl, sample timeout 60 s, bead
count 100, and gate settings 7,500–15,000 under standard PMT.
The data were analysed as described recently (38). Following
Clark’s theory interaction model, the titration curves were
used to determine the percentage of the half-maximal MFI
(mean fluorescence intensity) for the respective coupling control.
The MFI was multiplied with the reciprocal serum dilution
corresponding to the half-maximal MFI. The resulting MFI
values reflect the antigen binding intensity of antibodies
contained in each serum sample. Calculations were performed
using R (package 3.0.1) or GraphPad Prism version 5.0
(GraphPad Software).
Statistical Analysis
All statistical analyses were performed using GraphPad Prism
version 5.0 (GraphPad Software). The one-way ANOVAKruskal-
Wallis test with Dunn’s post-test was used to compare multiple
groups, while a Mann-Whitney U-test was used to compare two
groups in the analysis of the protection efficacy and IL-17A levels
in the nasal tissues or local/systemic humoral immune responses.
RESULTS
Selection and Purification of
Pneumococcal Lipoproteins
A previous in silico analysis of the pneumococcal genome
(S. pneumoniae strain D39) predicted more than 100
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surface-associated or secreted proteins, including 37 lipoproteins
(40). We selected 11 of these lipoproteins based on the following
criteria: (i) confirmed member of the lipoprotein cluster
(40), (ii) expressed in pneumococci (11, 17, 40), and (iii)
high levels of conservation (>85%, Table 3). The selected
lipoproteins included the four substrate-binding proteins
AdcAII, MetQ, PnrA, and PsaA, which are components of
ABC transporters responsible for the uptake of zinc(II),
methionine, nucleosides and manganese(II), respectively. We
also selected the following non-ABC transporter lipoproteins:
(i) the thioredoxins Etrx1 and Etrx2, which are involved
in pneumococcal resistance to oxidative stress, (ii) the L,D-
carboxypeptidase DacB, (iii) and the peptidyl-prolyl cis/trans
isomerases putative proteinase maturation protein A (PpmA)
and streptococcal lipoprotein rotamase A (SlrA). PpmA and
SlrA have a role in the folding or activation of the surface-
exposed proteins. The two other candidate lipoproteins, SP_0191
and SP_0899, are so far uncharacterised lipoproteins. With
the exception of the uncharacterised lipoproteins SP_0191
and SP_0899, previous studies using in vivo mouse models
have demonstrated that the selected lipoproteins are involved
in virulence (9–11, 14, 28, 32, 41, 42). It can therefore be
hypothesised that blocking these antigens, for example through
the use of specific antibodies, may lead to the attenuation
of virulence and thus confer protection. The lipoprotein-
encoding genes were therefore cloned into a pTP1 vector (10)
and plasmids were transformed into E. coli BL21 for protein
expression. The recombinant proteins were purified using affinity
chromatography, and their quality and purity was confirmed
using the silver staining of an SDS-gel and immunoblotting
(Figure 1). All lipoproteins were shown to be stable in solution,
and no degradation was observed.
Antigen-Specific Polyclonal IgGs and the
Surface Abundance of Pneumococcal
Lipoproteins
Mice were intraperitoneally immunised with the heterologously
expressed lipoproteins to generate antigen-specific antisera.
Purified polyclonal IgGs were used for immunoblot analyses,
which were performed using the whole-cell lysates of non-
encapsulated S. pneumoniae D39 and its isogenic lipoprotein-
deficient mutants. The immunoblots demonstrated that the anti-
lipoprotein IgGs are highly specific; the protein bands were only
detected in wild-type pneumococci but not in the corresponding
isogenic mutants (Figure 2A). Furthermore, under in vitro
growth conditions, the protein levels were highly variable, with
Etrx1, Etrx2, and SP_0899 showing the lowest levels and PnrA,
PsaA, and MetQ the highest levels of expression.
The recognition of pneumococci by the immune system
is vital for the host to clear these pathogens. The binding
of antigen-specific antibodies depends on the expression,
abundance and accessibility of antigens. In order to analyse the
surface abundance and accessibility of the selected lipoproteins,
we determined the relative antibody titres in mice following
immunisation. For this purpose, the recombinant lipoproteins
were immobilised in equimolar amounts and incubated with
FIGURE 1 | Pneumococcal lipoproteins heterologously expressed in E. coli. A
1-µg aliquot of heterologously expressed pneumococcal lipoproteins was
separated using SDS-PAGE and the proteins were detected using silver
staining (A) or with immunoblotting using a monoclonal mouse anti-Penta-His6
antibody and alkaline phosphatase-conjugated goat anti-mouse IgG (B).
serial dilutions of the polyclonal IgGs, and the initial IgG
concentrations were calculated from the resulting hyperbolic
titration curves. The highest IgG titres were measured for MetQ,
AdcAII, and PspA, while the lowest titres were observed for
Etrx1, Etrx2, and SP_0191 (Figure 2B). S. pneumoniae D39
and the non-encapsulated mutant D391cps were incubated
with increasing concentrations of polyclonal IgGs (1×, 5×,
10×, 20×, and 50×) to elucidate the abundance of the 11
selected lipoproteins on the pneumococcal surface using flow
cytometry. The initial IgG concentrations calculated in the
antibody titration study (Figure 2B), enabled the application
of comparable amounts of lipoprotein-specific IgGs in the
flow cytometric analysis. We used anti-PspA IgG as a positive
control, as it is already known that the choline-binding protein
PspA is highly abundant on the surface of these bacteria (43).
Overall, the antigen-specific IgGs bound in a dose-dependent
manner to the surface of pneumococci (Figure 2C, Table S1).
Our data confirm that PspA is probably one of the most
abundant pneumococcal surface proteins (Figure 2C, Table S1).
When using the highest anti-PspA antibody concentrations,
over 80% of the fluorescent pneumococci were detectable. Of
our tested lipoproteins, PnrA, PpmA, DacB, SP_0191, and SlrA
showed the highest surface abundance, with up to 60% positive
fluorescent events, while PsaA and MetQ had lower levels,
with approximately 40% of fluorescent pneumococci detectable.
The lowest surface abundance was observed for thioredoxins
Etrx1 and Etrx2, the putative lipoprotein SP_0899, and the
zinc transport system binding protein AdcAII, the latter two of
which were almost undetectable. Some of the tested proteins
were also accessible for antibody binding when covered by
the capsular polysaccharide. DacB, PpmA, SlrA, and MetQ
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TABLE 3 | Sequence homology of selected lipoproteins among different pneumococcal strains based on protein sequences from S. pneumoniae TIGR4.
S. p. strain AdcAII DacB Etrx1 Etrx2 MetQ PnrA PpmA PsaA SlrA SP0191 SP0899
TIGR4 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
D39 100.00 99.16 99.47 98.92 99.30 98.29 99.68 99.68 99.25 98.94 99.31
P1031 99.02 98.32 99.47 98.38 99.30 98.86 99.36 99.68 98.88 100.00 99.31
G54 99.02 96.64 100.00 98.92 98.24 98.57 93.15 99.35 99.25 100.00 98.97
Hungary19A 99.67 89.92 100.00 98.92 99.30 98.86 99.68 99.35 98.88 98.41 98.62
70585 99.34 89.08 99.47 100.00 99.65 98.86 100.00 99.68 99.25 100.00 99.31
JJA 100.00 86.97 100.00 100.00 99.65 98.57 99.68 96.76 99.63 100.00 98.89
Taiwan19F 100.00 86.97 100.00 100.00 99.65 98.57 99.68 99.68 99.25 98.94 99.31
could be detected in the presence of the capsule (Figure 2D,
Table S2). However, as expected, the binding capacity was
strongly diminished and the positive fluorescent events dropped
to 20–30%. Strikingly, the capsule does not block antibody
binding to PspA, confirming its exposure and accessibility for
antibodies (43). To confirm that IgG binding to S. pneumoniae
was antigen-specific, mutants deficient for the lipoproteins were
incubated with the corresponding polyclonal IgGs. We detected
onlyminor non-specific IgG binding for some of the lipoproteins,
indicating that the generated antibodies were overall antigen-
specific (Figure S1).
PnrA, DacB, MetQ, and PsaA Are Highly
Immunogenic
The immunogenicity of the selected lipoproteins was investigated
using multiplex immunoassay technology. Two different types of
sera were analysed: (i) convalescent patient sera and (ii) antisera
from mice intraperitoneally immunised with pneumococcal
antigens using Alum as the adjuvant (Figure 3). Recombinant
proteins covalently coupled to fluorescent MagPlex R© beads
were incubated with serial dilutions of human or mouse sera.
Measurements of convalescent patient sera revealed the highest
IgG levels for PsaA and PnrA, which were both comparable to
those of the positive control, PspA (Figure 3A). DacB, PpmA,
and Etrx1 IgG levels were also high, although they were an
order of magnitude lower than those for PsaA. The titres of
antibodies for Etrx2, AdcAII, MetQ, SP_0191, SP_0899, and
SlrA were comparatively low in randomly selected convalescent
sera. The final antibody titres of mouse sera obtained 2 weeks
after the third and final immunisation ranged from 2.9 × 106
AU (α-PspA) to 1.8 × 108 AU (α-PsaA), and were at least
three orders of magnitude higher than the titres of the pre-
immune sera. The highest antibody titres were measured for
PsaA, MetQ, AdcAII, and DacB. The second boost did not
substantially increase the antibody titres, which were on average
only 2.5-fold higher than the levels measured after the first
booster immunisation. Notably, the changes in antibody titres
for MetQ and DacB were highly similar when compared between
individual mice. However, the antibody titres for the majority
of the other lipoproteins varied substantially. In conclusion,
lipoproteins such as DacB, MetQ, and PnrA represent promising
candidates for the development of a robustly effective and reliable
vaccination.
Intranasal Vaccination With DacB, MetQ, or
PnrA Reduces Pneumococcal Load in the
Nasal Cavity
Based on the previous screenings, three lipoproteins DacB,
PnrA, and MetQ were selected to assess whether their use
in an intranasal vaccination would confer protection against
pneumococcal colonisation. Mice were intranasally immunised
with the protein candidates in combination with CTB as an
adjuvant, and received two booster immunisations. PspA was
included as a positive control, while PBS mock-treated mice were
used as a negative control. Three weeks after the final vaccination,
the mice were intranasally infected with a non-lethal dose of
3.4 × 106 S. pneumoniae D39. Three days post-infection, mice
were euthanised and live pneumococci were recovered from
their nasal tissues. Consistent with previous studies, an intranasal
vaccinationwith PspA induced the strongest reduction (263-fold)
of bacterial load in the nasal cavity when comparing the bacterial
load to mock-treated mice (Figure 4A). PnrA also showed
strong efficacy, causing a 58-fold reduction in the number of
S. pneumoniae in the nasopharynx. Of the mice, which received
the PnrA immunisation, 50% had almost completely cleared the
pneumococci within 3 days post-infection. Immunisation with
DacB and MetQ showed a trend in reducing the bacterial load.
However, reduction was only 14- or 4-fold, respectively, and not
statistically significant.
Protective Immunity Correlates With
Increased Intranasal IL-17A Levels
Immunity to S. pneumoniae infection was shown to be dependent
on the induction of IL-17A-secreting CD4+ T cells, leading
to the recruitment of neutrophils to enable the clearance of
the pneumococci (44–46). To determine the role of IL-17A in
our protection studies, we quantified the levels of this cytokine
in the nasal tissues of mice immunised with DacB, MetQ,
or PnrA 3 days after infection. Significantly increased IL-17A
levels were identified in the DacB- and PnrA-immunised mice
in comparison with the negative control, both reaching IL17A
levels comparable to mice immunised with PspA (Figure 4B).
Importantly, production of nasopharyngeal IL-17A significantly
correlated with the level of protective immunity induced by the
pneumococcal lipoproteins (ρ = −0.3916; p = 0.002), which
was indicated by a Spearman correlation test (Figure S2). These
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FIGURE 2 | Pneumococcal lipoproteins are highly abundant on the pneumococcal surface. (A) In immunoblots, the specificity of antisera derived from intraperitoneal
immunisations of CD-1 mice (n = 6) with recombinant lipoproteins was assessed. Therefore, the wild-type strain S. pneumoniae D391cps and the corresponding
isogenic lipoprotein deficient mutants (2 × 108 bacteria per lane) were used. Enolase was detected with a rabbit anti-enolase serum and served as a loading control.
(B) IgG antibody titrations were performed by incubating equimolar amounts of recombinant proteins with serial dilutions of isolated polyclonal IgGs. Detection was
carried out using a peroxidase-coupled goat anti-mouse IgG followed by incubation with OPD as a substrate and absorbance was measured at 492 nm. Titrations
were performed at least three times and the error bars represent the SEM. (C,D) Using the equation for the hyperbolic regression curve (y [Abs] = Bmax·x
Kd+x
, Bmax,
maximal binding; Kd, concentration for half maximal binding) an initial IgG concentration was calculated in the linear dynamic range. The polyclonal IgGs with equal
contents of IgG specific for each lipoprotein were therefore applied to enable the comparison of their surface abundances. In a flow cytometric approach, D391cps
(C) and D39 (D) were incubated with the appropriate calculated concentration of IgG and concentrations 5-, 10-, 20-, and 50-fold greater to analyse the surface
abundance of the selected lipoproteins. Antibody binding was detected using a goat anti-mouse Alexa Fluor® 488-coupled secondary antibody. The percentage of
positive gated events is depicted in the graphs, thereby indicating the proportion of wild-type bacteria positive for the binding of the respective anti-lipoprotein IgGs.
The mean values of at least three independent experiments are shown, with error bars corresponding to SEM.
results confirm the important role of IL-17A in protecting against
pneumococcal colonisation.
Intranasal Immunisation Only Partially
Induces Local and Systemic
Antigen-Specific Antibodies
Humoral immune responses following intranasal immunisation
with recombinant lipoproteins were investigated by analysis of
antibody kinetics in post-immune antisera and the local antibody
titres in nasal tissues harvested 3 days after infection with
pneumococci. As shown in Figure 5A, intranasal immunisation
with recombinant MetQ, PnrA, and PspA induced strong
systemic antigen-specific antibody responses in all tested mice.
However, a substantial systemic IgG response for recombinant
DacB was only detected in one of the six mice. Three
days after infection, we analysed the local humoral immune
responses in the nasal tissues of all mice used in the model of
colonisation (n = 12) to elucidate whether lipoprotein-specific
immunoglobulins are present in the nasal cavity, which might
contribute to protection (Figures 5B,C). MetQ and PspA were
found to be potent immunogens when administered intranasally,
as demonstrated by the resulting high local titres of IgG,
while the local IgG response for PnrA was significantly lower
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FIGURE 3 | Analysis of convalescent patient sera and mouse sera derived from intraperitoneal immunisations indicate the high immunogenicity of PnrA, DacB, and
MetQ. (A) A total of 22 antisera from convalescent patients who suffered from pneumococcal infections such as pneumonia (n = 6), meningitis (n = 7), sepsis (n = 4),
and unknown clinical outcomes (n = 5) caused by different pneumococcal serotypes were analysed to compare their levels of anti-lipoprotein antibodies. Each symbol
represents a single antiserum, while the different colours indicate the clinical outcome of every patient. (B) The immunogenicity of the lipoproteins was further
demonstrated by analysing the antibody kinetics of intraperitoneally immunised CD-1 mice (n = 6). The mice received three vaccinations with 20 µg antigen and Alum
as the adjuvant, with a 2-week interval between treatments. Before each treatment and 2 weeks after the final immunisation, antisera were collected to enable the
determination of the antibody kinetics. Each individual mouse is depicted in the graphs. All serum samples were serially diluted and measured using the FLEXMAP
3D® system. Response values reflect the levels of antigen-specific IgG for the 11 tested lipoproteins and the positive control PspA.
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FIGURE 4 | Intranasal vaccinations with the lipoproteins MetQ, DacB or PnrA reduce pneumococcal colonisation and increase local IL-17A levels. Bacterial recovery
of S. pneumoniae D39 from nasal tissue (A) and nasopharyngeal IL-17A levels (B) 3 days after the intranasal challenge of C57BL/6 mice (n = 12) with 3.4 × 106 CFU.
Each mouse received three intranasal immunisations with 5 µg of one of the four recombinant proteins, MetQ, DacB, PnrA, or PspA, in combination with 4 µg CTB in
2-week intervals. The data were statistically analysed using a Kruskal Wallis test accompanied by Dunn’s multiple comparison post-test, with all conditions compared
to control mice that received an intranasal treatment with PBS and CTB. Symbols indicate individual mice, bars represent the group median, and the dotted line
indicates the lower limit of detection. **p < 0.01; ***p < 0.001.
(Figure 5B). The local IgG response for DacB was substantially
lower than MetQ and PspA, which was consistent with the
antibody kinetics. Intranasal immunisation with PspA or MetQ
induced considerable levels of local antigen-specific IgA, whereas
nasal IgA for PnrA and DacB were almost too low to be detected
(Figure 5C). Taken together, these data suggest that local and
serum antigen-specific antibody responses might not perfectly
correlate with protection in vivo, as was especially shown for
PnrA and DacB.
Immunisations With DacB, MetQ, or PnrA
Predominantly Induce IgG1 Responses
To shed light on the type of immune response induced
by the intraperitoneal or intranasal vaccinations with our
candidate proteins in combination with Alum or CTB
as the adjuvant, respectively, we determined the IgG1
and IgG2a/IgG2c levels in post-immune sera (Figure 6).
Overall, intraperitoneal immunisation with the lipoproteins
DacB, MetQ and PnrA elicited higher total IgG responses
than intranasal immunisation (Figures 6A,C). Immunising
mice either intranasally or intraperitoneally with the four
pneumococcal antigens predominantly led to high IgG1
and lower but still substantial levels of IgG2, suggesting
a Th2-biased response (Figures 6B,D). The intranasal
immunisation with DacB resulted in a remarkably high
IgG1/IgG2 ratio and a very weak humoral immune response
overall (Figure 6B). In summary, intranasal immunisation
with the lipoproteins DacB, MetQ, and PnrA reduced
pneumococcal colonisation, and the level of protection
correlated with IL-17A levels. However, immunisation only
partially induced local and systemic antigen-specific antibody
responses.
DISCUSSION
Pneumococcal colonisation of the upper respiratory tract is
a prerequisite for invasive disease (47). Higher colonisation
rates facilitate the transmission of this opportunistic pathogen
from host to host, enabling pneumococci to spread within a
population, as was shown in influenza A co-infection mouse
models (48). Protein-based vaccines should therefore include one
or more antigens that reduce nasopharyngeal colonisation to
prevent infectious diseases and the shedding of pneumococci.
In order to elicit serotype-independent protection, conserved
pneumococcal surface proteins are of special interest. Previous
studies have already shown that PsaA, a highly conserved
manganese-binding lipoprotein, provides cross-protection in a
mouse model of colonisation following intranasal immunisation
(23). Here, we selected 11 pneumococcal lipoproteins with high
sequence homology (>85%) and investigated their potential for
use as subunits of such a vaccine.
The expression and surface accessibility of potential vaccine
candidates is important for the host immune system to recognise
and counteract the dissemination of pneumococci to normally
sterile body sites. Under in vitro growth conditions in a rich
medium, the highest surface abundance of lipoproteins was
observed for PpmA, PnrA, and DacB, while AdcAII and the
thioredoxins Etrx1 and Etrx2 were detected at a substantially
lower abundance. The highest surface abundance was shown
for the choline-binding protein PspA, a major virulence
factor of pneumococci known to be highly immunogenic
and abundant on the surface (43, 49). The pneumococcal
capsular polysaccharide (CPS) is known to mask surface-
exposed antigens, thereby blocking opsonisation by inhibiting
antibody binding and consequently limiting pathogen uptake
by professional phagocytes. Indeed, we also indicate that
the detection of surface-localised lipoproteins was decreased
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FIGURE 5 | Intranasal immunisation with lipoproteins induces lower local and systemic humoral immune responses. (A) Six C57BL/6 mice used for the in vivo
colonisation model were randomly selected for the analysis of their antibody kinetics following an intranasal immunisation with the lipoproteins MetQ, DacB, and PnrA.
The mice received three doses with 5 µg antigen and 4 µg CTB as the adjuvant in 2-week intervals. Before each treatment and 2 weeks after the third immunisation,
antisera were collected to determine the antibody kinetics. The data from each individual mouse are depicted for every protein. Antisera were serially diluted and
measured using the FLEXMAP 3D® system. The response values reflect the levels of antigen-specific IgG. (B,C) Three weeks after the final immunisation, the mice
were challenged with S. pneumoniae D39 (3.4 × 106 CFU) and 3 days after infection their nasal tissues were harvested, homogenised and analysed for local
antigen-specific IgG (B) and IgA (C) using ELISA. The IgG and IgA levels were determined using a 1:10 or 1:2 dilution of the nasal homogenate, respectively. The data
were statistically analysed using a Mann-Whitney U-test. Symbols represent individual mice (n = 12) and the bars represent the group median. *p < 0.05; **p < 0.01;
***p < 0.001.
when using the encapsulated strain D39, while the CPS only
marginally diminished antibody binding to PspA, consistent
with the findings of previous studies (43). The presence of
the CPS could not completely inhibit antibody binding to
the surface-exposed lipoproteins, however, as indicated by the
dose-dependent increase of fluorescence intensities in the flow
cytometric analysis. In previous studies, the iron uptake ABC
transporter lipoproteins PiaA and PiuA and the nucleoside-
binding lipoprotein PnrA were shown to be surface accessible.
Indeed, antigen-specific antibodies bound to encapsulated
pneumococci, but cross-reactivity to heterologous strains was
only demonstrated for the PnrA-specific antibodies, suggesting
that PnrA is conserved across pneumococcal serotypes (11, 50).
It was previously reported that anti-PsaA and anti-PpmA failed to
detect PsaA and PpmA on the surface of different pneumococcal
strains (49), in contrast to our findings. The differences in
the accessibilities of the analysed lipoproteins could be due
to the variable capsular structures and expression levels, their
localisation in the cell wall, and especially the different levels
of expression for each lipoprotein gene. The latter point must
be seriously evaluated when searching for a new protein-based
vaccine, because several studies have shown that pneumococcal
gene expression is highly dependent on the strain and the host
compartment in which the pneumococci reside (51–55).
To evaluate the humoral immune responses induced by
the selected pneumococcal lipoproteins, a multiplex bead-based
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FIGURE 6 | Intraperitoneal and intranasal immunisations with DacB, MetQ, or PnrA predominantly induce IgG1 responses. Antigen-specific total IgG, IgG1, and IgG2
titres were monitored using an ELISA in either post-immune sera following an intraperitoneal immunisation with Alum as the adjuvant (A,B) or in post-challenge sera
obtained after intranasal immunisation with CTB as the adjuvant followed by an intranasal challenge with S. pneumoniae D39 (C,D). Antibody titres of each serum
specimen are denoted as the log10 of the reciprocal dilution of the serum giving twice the average absorbance of the sera derived from the PBS-treated group. The
data were statistically analysed using a Mann-Whitney U-test. Symbols represent individual mice (n = 6 for Alum group, n = 12 for CTB group) and bars represent the
group median. *p < 0.05; **p < 0.01; ***p < 0.001.
immunoassay was performed. Our analysis of convalescent
patient sera revealed high antibody titres for the lipoproteins
PsaA, PnrA, PpmA, and DacB. Therefore, we concluded that
these lipoproteins are immunogenic during natural infections.
PspA elicited an exceptionally high humoral immune response,
as also reported previously (36, 56). We further investigated the
immunogenicity of the selected lipoproteins in an immunisation
study using intraperitoneally vaccinated mice. High endpoint
antibody titres were measured for PsaA, DacB, PnrA, MetQ, and
AdcAII. Immunisation with DacB and MetQ was particularly
effective, rapidly increasing the antibody titres in all mice. Inmost
cases the first booster immunisation was sufficient to elicit high
antibody responses, suggesting that a two-dose immunisation
strategy may be sufficient for accomplishing an optimal
humoral immune response. Taken together, these data show that
pneumococcal lipoproteins are generally highly immunogenic.
Lipoproteins are able to elicit humoral immune responses during
natural pneumococcal colonisation or infections, as shown for
PsaA, PnrA, and DacB (20–22, 56, 57), and may also be used in
immunisation to induce a substantial immune response. These
findings are strongly supported by several other studies using
different lipoproteins as vaccine antigens, including PsaA, PnrA,
PiuA, and PiaA (11, 23, 58).
As mentioned above, colonisation is the first step towards
the establishment of pneumococcal infections Hence, protection
against colonisation is a crucial aspect of pneumococcal vaccine
development. Based on the surface abundances, accessibility
and immunogenicity of the lipoproteins, we selected DacB,
MetQ, and PnrA for the assessment of their protective
potential in a mouse model of colonisation. Subcutaneous
immunisation with PnrA was previously shown to induce
protective immunity against an intraperitoneal challenge with
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heterologous S. pneumoniae strains (11). In the present work,
we further confirmed the potential of PnrA as a component
of protein-based subunit vaccines. Its use in the intranasal
immunisation of mice significantly decreased the bacterial loads
in the nasal cavity. Immunization with DacB and MetQ only
tended to reduce bacterial load in the nasal cavity to an
insignificant extent. Basavanna et al. indicated that systemic
vaccination with MetQ does not extend the survival or result
in differences in the progression of fatal infections. Based on a
transcriptome analysis, they reasoned that this lack of protection
might be due to the low expression of metQ in infection-
related niches (12). This might be the critical factor causing
the comparatively low protective effect of MetQ immunisation
against pneumococcal colonisation in our study.
The pro-inflammatory cytokine IL-17, among others secreted
by Th17 cells, is essential for recruitment and activation
of macrophages and neutrophils to the nasopharynx, a
process critical for clearing pneumococci from the host (59).
Th17-mediated immunity is essential for protection against
pneumococcal colonisation, as CD4+ T cell-derived IL-17,
but not IFNγ or IL-4, is required for the clearance of
colonisation (46). Furthermore, intranasal immunisation with
pneumococcal whole-cell antigens or a subunit-protein vaccine
was found to provide IL-17-mediated, but antibody-independent,
protection (45). Here, we monitored that the nasal tissues
of mice vaccinated with DacB, PnrA, and PspA showed
significantly increased IL-17A levels 3 days after infection with
pneumococci that correlated with protection. These elevated
local IL-17A concentrations probably result from recall responses
of immunization-induced memory towards these antigens.
Accordingly, the immunisation of mice withMetQ, which caused
the lowest reduction in bacterial load, provoked only a slight
increase in IL-17A levels. Consistent with our results, strong
correlations between high IL-17A levels and protection against
colonisation have been reported in previous studies, where
increased ex vivo IL-17A was predictive of in vivo nasal IL-17A
levels following vaccination and, furthermore, was an indicator
of protective efficacy (60, 61).
CTB is a potent adjuvant with various immunomodulatory
functions, which are mainly attributed to its ability to bind
to monosialotetrahexosylganglioside (GM1). GM1 is broadly
distributed in a variety of cell types, including the epithelial cells
of the gut and antigen-presenting cells, macrophages, dendritic
cells, and B cells. Therefore, CTB can enhance the immune
responses to bystander antigens, a phenomenon indicated by the
production of effective antigen-specific antibodies at the mucosal
surfaces (62–65). Immunity to pathogens at mucosal surfaces is
especially driven by antigen-specific secretory IgA (sIgA), which
acts as an inhibitor of adherence and inflammation and is able
to neutralise viruses, toxins and enzymes (66–70). Here, we
showed that intranasal immunisation with PspA plus CTB had
the strongest effect on the reduction of pneumococcal load in the
nasal cavity. We could only detect considerable local IgA levels in
a few mice immunised with PspA and CTB, although they were
still significantly higher than those found for DacB and PnrA. In
contrast, substantial amounts of nasal IgGwere detected for PspA
and MetQ, though significantly less DacB- and PnrA-specific
local IgG was identified. After either intranasal immunisation
with CTB followed by a challenge with S. pneumoniae D39
or intraperitoneal immunisation with Alum as the adjuvant,
the systemic humoral immune responses varied depending on
the antigen and route of immunisation. Overall, they were
characterised by a predominance for IgG1 and substantial
IgG2a/IgG2c production, suggesting a primary Th2 response,
which is consistent with previous studies and was attributed to
the use of Alum as adjuvant (63, 71, 72). While intraperitoneal
immunisation with DacB and Alum as an adjuvant led to a
strong systemic antibody response, the intranasal administration
of DacB in combination with CTB induced only marginal
levels of IgG production. The opposite was observed for PspA,
where intranasal immunisation provoked higher antibody titres
compared with the intraperitoneal administration. It is unclear
why PspA is a potent immunogen when administered in
combination with CTB via the nasal route but less immunogenic
in a systemic vaccination using Alum as an adjuvant; however,
our results are in accordance with a previous study using a
different mouse strain and a slightly different immunisation
protocol (73). It has been reported that the efficient induction
of an immune response depends on the adjuvant, the route
of immunisation and the immunogenicity of the antigen itself
(74, 75). Both Alum and CTB represent potent adjuvants, as
the antibody titres for at least two proteins in our vaccinations
were highly elevated. This further indicates that, in principle,
our tested lipoproteins are immunogenic, a fact supported by
the analysis of convalescent patient sera. It therefore seems
likely that the route of immunisation has a profound role on
the magnitude of the immune response. In a vaccination study
where rats were immunised with three structurally different types
of pneumococcal polysaccharide (PPS-3, PPS-4, and PPS-14)
using four immunisation routes, remarkable differences were
observed in both the magnitude of the immune response and
the distribution of the isotypes (76). The authors concluded that,
besides the route of immunisation, the structural features of
the pneumococcal polysaccharides have a pivotal influence on
the elicited immune response. Likewise, structural differences
of the proteins could be one of the reasons for the varying
immune responses in vivo. Although intranasal vaccination
with DacB could not induce high levels of antigen-specific
antibody production, it had a drastic effect on the reduction of
pneumococcal colonisation accompanied by elevated local levels
of IL-17. This suggests that protection is rather characterised by
a cellular immune response mediated by local antigen-specific
CD4+ memory T cells than by a humoral immune response.
Accordingly, in a previous study it was shown that protection
against pneumococcal colonisation by intranasal immunisation
with three pneumococcal proteins (PspC, PsaA, and PdT) was
dependent on CD4+ T cells but independent of antibodies (45).
It therefore remains unclear whether local or systemic antibody
responses, especially towards DacB, result in the protective
effect in the mouse model of colonisation following intranasal
immunisation.
In conclusion, we showed that vaccination of mice with a
monovalent protein-based vaccine containing the lipoprotein
PnrA impairs nasopharyngeal colonisation by pneumococci
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after intranasal challenge with S. pneumoniae D39. There
was a possible protective effect for DacB and MetQ as
vaccine candidates, although it was less pronounced and not
significant. The lipoproteins evaluated here are highly conserved
among pneumococcal serotypes, abundant on the pneumococcal
surface, and immunogenic. These properties mean they are
promising protein antigens for a next-generation subunit
vaccine for the reduction of pneumococcal colonisation, which
could be accompanied by a decline in the transmission of
pneumococcal infections. Future studies are required to elucidate
the mechanisms of protective immunity induced by these
lipoproteins and to identify the optimal route of immunisation
and appropriate adjuvant.
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